Navigation Links
Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
Date:2/20/2008

Conference Call and Webcast to Follow

THE WOODLANDS, Texas, Feb. 20 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its fourth quarter and year end 2007 financial results on Thursday, March 6, 2008 after the financial markets close. Lexicon management will hold a conference call to discuss its clinical development progress, financial results for 2007 and financial guidance for 2008 at 5:00 p.m. Eastern Time on March 6, 2008.

The dial-in number for the conference call is 877-681-3378 (within the United States) or 719-325-4842 (international). The pass code for all callers is 7721341. Investors can access a live webcast of the call at http://www.lexpharma.com. An archived version of the webcast will be available on the website through March 11, 2008.

About Lexicon

Lexicon is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Lexicon currently has development programs underway for such areas of major unmet medical need as irritable bowel syndrome, cognitive disorders, autoimmune diseases, and carcinoid syndrome. The company has used its proprietary gene knockout technology to discover more than 100 promising drug targets and create an extensive pipeline of clinical and preclinical programs in the therapeutic areas of cardiology, gastroenterology, immunology and oncology, metabolism, neurology and ophthalmology. To advance the development and commercialization of its programs, Lexicon is working both independently and through collaborators including Bristol-Myers Squibb Co., Genentech, Inc. and N.V. Organon. For additional information about Lexicon a
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
2. Lexicon Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
3. Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference
4. Lexicon Pharmaceuticals Reports 2007 Third Quarter Financial Results
5. Lexicon to Report Third Quarter 2007 Financial Results on October 30, 2007
6. Lexicon Pharmaceuticals to Present at Bio InvestorForum
7. Lexicon Pharmaceuticals to Present at ThinkEquity ThinkClinic
8. Lexicon Appoints Judith Swain, M.D. to Board of Directors
9. Lexicon Pharmaceuticals to Present at the UBS Global Life Sciences Conference
10. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
11. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... May 28, 2015 In two different ... L. Sherley, M.D., Ph.D., will present the company’s unique ... In a conference talk, he will describe Asymmetrex ... designs with computer simulation to produce the first-ever technology ... and quality over time in culture. When leading ...
(Date:5/27/2015)... DUBLIN , May 26, 2015 ... addition of the "Global Breast Cancer Monoclonal ... offering. Globally, Roche seems to dominate ... largest inventory. Its block buster molecule, Herceptin has ... years. It was found that breast cancer cells ...
(Date:5/27/2015)... The ALS Therapy Development Institute ... owned subsidiary, Anelixis Therapeutics , $1.5 million toward ... targets the innate immune system. The funding comes from ... from the 2014 social media phenomenon known as the ... million raised directly by the Institute through last year’s ...
(Date:5/27/2015)... THOUSAND OAKS, Calif. , May 27, 2015 /PRNewswire/ ... company, has been awarded a U.S. patent for a ... gene in areas such as research, product development and ... useful in regulating key biosynthetic processes that are the ... to offer other seed companies a commercial license to ...
Breaking Biology Technology:Asymmetrex Will Discuss the Importance of Adult Tissue Stem Cell Time with 3D Tissue Engineers at the 14th Annual World Preclinical Congress in Boston in June 2Asymmetrex Will Discuss the Importance of Adult Tissue Stem Cell Time with 3D Tissue Engineers at the 14th Annual World Preclinical Congress in Boston in June 3Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 2Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 3Ice Bucket Challenge Advances Antibody Toward Clinical Trial for ALS 2Ice Bucket Challenge Advances Antibody Toward Clinical Trial for ALS 3Ceres Awarded Patent for Innovation in Soybean 2Ceres Awarded Patent for Innovation in Soybean 3
... 28 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ... (NASDAQ: ATHX) announced positive results from its phase ... therapy product, administered to individuals following acute myocardial ... heart attack. The study results, which represent at ...
... CLEVELAND, Ohio , ... leading provider of medical education and simulation training,products for ... the company,s continued global expansion. Simbionix has increased,the size ... of its Corporate,Headquarters in Cleveland, OH , and ...
... Researchers have discovered mechanisms critical to interactions between hot ... fusion reactor, part of work aimed at developing coatings ... Fusion powers the stars and could lead to ... plant would produce 10 times more energy than a ...
Cached Biology Technology:Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 2Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 3Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 4Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 5Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 6Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 7Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 8Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 9Simbionix Continues its Global Expansion 2Findings show promise for nuclear fusion test reactors 2Findings show promise for nuclear fusion test reactors 3
(Date:5/19/2015)... 2015 Fingerprint Cards (FPC) has received ... FPC1155 and FPC1035 from one if its module partners. Deliveries ... Q3 2015 and the sensors will be used by smartphone ... for 2015 hereby amount to 740 MSEK to date. In ... MSEK and a number of smaller orders not separately communicated ...
(Date:5/14/2015)... 14, 2015  Verificient Technologies, Inc., a ... online remote proctoring, announced a new alliance ... and creator of the Canvas Learning Management ... companies will benefit from the seamless integration ... As a fully integrated multifactor biometrics behavioral ...
(Date:5/8/2015)... Calif. , May 8, 2015 Synaptics Inc. ... solutions, today announced that members of the executive management team ... Morgan 43rd Annual Technology, Media and Telecom Conference Date: ... Hotel in Boston, MA ... 27, 2015 Time: 2:45pm ET Location: The New York Palace ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Synaptics to Present at Upcoming Investor Conferences 2
... consume foods purchased in vending machines are more likely to ... with being overweight, obese or at risk for chronic health ... research from the University of Michigan Medical School. The ... bars and other related sales that compete with USDA lunch ...
... PASADENA, Calif.Researchers at the California Institute of Technology ... carbon just one atom thickto visualize the structure of ... first direct images of how water coats surfaces at ... potentially unlimited number of other molecules, including antibodies and ...
... A new study from the Center for Interdisciplinary Chronobiological ... additional link between Light At Night (LAN) and cancer. ... out at the University of Haifa that also established ... ,environmental light pollution, which the study has shown is ...
Cached Biology News:Children who eat vended snack foods face chronic health problems, poor diet 2Caltech chemists develop simple technique to visualize atomic-scale structures 2Caltech chemists develop simple technique to visualize atomic-scale structures 3Connection between light at night and cancer revealed in additional study 2